Yani He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yani He has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Jia Chen
Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, 400042, China
11 shared publicationsKe-Hong Chen
Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China
5 shared publicationsKehong Chen
Department of Nephrology, Daping Hospital Army Medical University Chongqing China
5 shared publicationsLi-Ming Wang
Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, 400042, China
5 shared publicationsJia Luo
Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, 400042, China
4 shared publicationsJie Yang
Department of Nephrology, Daping Hospital Army Medical University Chongqing China
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Advances in the study of sodium-glucose cotransporter 2 inhibitors for peritoneal dialysis
- 15 September 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Open AccessAdvances in the study of sodium-glucose cotransporter 2 inhibitors for peritoneal dialysis
- Open Access
- 22 August 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (16) , e70800
Decoy Receptor 2 as a Cell Cycle Arrest Biomarker for Predicting Renal Recovery Following Acute Kidney Injury
Renal recovery following acute kidney injury (AKI) is a key determinant of long‐term prognosis, while non‐recovery significantly increases the risk of chronic kidney disease and progression to end‐stage renal disease. Although cell cycle arrest is implicated in renal non‐recovery and fibrosis, its association with decoy receptor 2 (DcR2) remains unclear. In this study, we evaluated 139 patients with biopsy‐confirmed AKI, defining renal non‐recovery as a ≥ 50% increase in baseline serum creatinine (Cr) or the initiation of dialysis. Patients were divided into recovery (n = 79) and non‐recovery (n = 60) groups. Urinary DcR2/creatinine (uDcR2/Cr) levels were significantly higher in non‐recovery cases, with an area under the curve of 0.733 and a diagnostic cut‐off of 378 ng/gCr. Elevated uDcR2/Cr predicted poor renal survival and was independently correlated with non‐recovery. In mouse models of ischemia–reperfusion‐induced AKI, increased urinary and tubular DcR2 levels were also associated with impaired recovery. Proteomics analysis revealed GSK3b enrichment in cell cycle pathways. Functional studies showed that DcR2 mediated cell cycle arrest through GSK3b/cyclin D1 signalling. In conclusion, DcR2 functions as a biomarker of cell cycle arrest and renal recovery, offering both diagnostic and mechanistic insights, and may serve as a potential therapeutic target in AKI.
- 22 August 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (16) , e70800
Open AccessDecoy Receptor 2 as a Cell Cycle Arrest Biomarker for Predicting Renal Recovery Following Acute Kidney Injury
Renal recovery following acute kidney injury (AKI) is a key determinant of long‐term prognosis, while non‐recovery significantly increases the risk of chronic kidney disease and progression to end‐stage renal disease. Although cell cycle arrest is implicated in renal non‐recovery and fibrosis, its association with decoy receptor 2 (DcR2) remains unclear. In this study, we evaluated 139 patients with biopsy‐confirmed AKI, defining renal non‐recovery as a ≥ 50% increase in baseline serum creatinine (Cr) or the initiation of dialysis. Patients were divided into recovery (n = 79) and non‐recovery (n = 60) groups. Urinary DcR2/creatinine (uDcR2/Cr) levels were significantly higher in non‐recovery cases, with an area under the curve of 0.733 and a diagnostic cut‐off of 378 ng/gCr. Elevated uDcR2/Cr predicted poor renal survival and was independently correlated with non‐recovery. In mouse models of ischemia–reperfusion‐induced AKI, increased urinary and tubular DcR2 levels were also associated with impaired recovery. Proteomics analysis revealed GSK3b enrichment in cell cycle pathways. Functional studies showed that DcR2 mediated cell cycle arrest through GSK3b/cyclin D1 signalling. In conclusion, DcR2 functions as a biomarker of cell cycle arrest and renal recovery, offering both diagnostic and mechanistic insights, and may serve as a potential therapeutic target in AKI.
- Open Access
- 5 April 2025
- Published by Springer Nature in Diagnostic Pathology
- Vol. 20 (1) , 1-5
Normolipidemic lipoprotein glomerulopathy with IgA nephropathy — ApoE Kyoto mutation: a case report
Lipoprotein glomerulopathy (LPG), a rare genetic metabolic kidney disease with poor prognosis, is caused by mutations in the apolipoprotein E (ApoE) gene and is usually accompanied by hyperlipidemia. Lipoprotein glomerulopathy can be complicated by other glomerulopathies, such as membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy (IgAN), which have been mainly reported in Japan. Herein, we present the first case of a patient with LPG with IgAN from Chongqing, China. In contrast to previous cases, this patient lacked hyperlipidemia and ApoE was a Kyoto mutation. A 38-year-old man was admitted to our hospital due to proteinuria and hematuria, which was found during urine examination. Renal function and blood lipid and lipoprotein levels were normal. After renal biopsy, the patient was diagnosed of LPG with IgAN. Analysis of the ApoE gene showed a heterozygous C→T transition in exon 3, resulting in a change in the 25th amino acid from arginine to cysteine (Kyoto mutation). Genetic analysis of the family showed that this mutation was inherited from his father and passed on to his daughter. Serum ApoE was 14.4 mg/dL. Combined with the above findings, the patient was diagnosed with LPG accompanied by IgAN. After 18 months of enalapril treatment without lipid-lowering therapy, the patient’s renal function and blood lipid levels were stable and urine protein levels were significantly ameliorated. We presented a rare case of LPG (Kyoto) with IgAN without abnormal blood lipids and other typical clinical manifestations. Therefore, for patients with unremarkable clinical manifestations, renal biopsy is of great value for definite diagnosis of disease.
- 5 April 2025
- Published by Springer Nature in Diagnostic Pathology
- Vol. 20 (1) , 1-5
Open AccessNormolipidemic lipoprotein glomerulopathy with IgA nephropathy — ApoE Kyoto mutation: a case report
Lipoprotein glomerulopathy (LPG), a rare genetic metabolic kidney disease with poor prognosis, is caused by mutations in the apolipoprotein E (ApoE) gene and is usually accompanied by hyperlipidemia. Lipoprotein glomerulopathy can be complicated by other glomerulopathies, such as membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy (IgAN), which have been mainly reported in Japan. Herein, we present the first case of a patient with LPG with IgAN from Chongqing, China. In contrast to previous cases, this patient lacked hyperlipidemia and ApoE was a Kyoto mutation. A 38-year-old man was admitted to our hospital due to proteinuria and hematuria, which was found during urine examination. Renal function and blood lipid and lipoprotein levels were normal. After renal biopsy, the patient was diagnosed of LPG with IgAN. Analysis of the ApoE gene showed a heterozygous C→T transition in exon 3, resulting in a change in the 25th amino acid from arginine to cysteine (Kyoto mutation). Genetic analysis of the family showed that this mutation was inherited from his father and passed on to his daughter. Serum ApoE was 14.4 mg/dL. Combined with the above findings, the patient was diagnosed with LPG accompanied by IgAN. After 18 months of enalapril treatment without lipid-lowering therapy, the patient’s renal function and blood lipid levels were stable and urine protein levels were significantly ameliorated. We presented a rare case of LPG (Kyoto) with IgAN without abnormal blood lipids and other typical clinical manifestations. Therefore, for patients with unremarkable clinical manifestations, renal biopsy is of great value for definite diagnosis of disease.
- Open Access
- 22 February 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Correlation between intradialytic blood pressure variability and cognitive impairment in patients on maintenance hemodialysis
The relationship between intradialytic blood pressure variability (BPV) and mild cognitive impairment (MCI) in maintenance hemodialysis (MHD) patients is currently unclear. Our present study aimed to illustrate the correlation between intra-dialysis BPV and CI in MHD patients. Intradialytic SBP within 3 months before cognitive assessment of the patients were collected as baseline data and averaged as final data. The intradialytic SBP was converted to the following 4 candidate short-term BPV indices: standard deviation (SD), coefficient of variation (CV), average real variability (ARV), RANGE. Overall cognitive function was assessed by the Montreal Cognitive Assessment (MoCA) scale. The study finally enrolled 170 patients with 6662 dialysis records and 26,580 SBP measurements. The mean age of the patients was 57.99 years, the MCI prevalence was 78.24%. Intradialytic SBP ARV (average real variability) was notably higher in patients with MCI than in the non-MCI (NMCI) group (8.91 vs. 7.60, P = 0.042), but there was no statistical difference in the mean SBP and other BPV indices between the two groups. There was a non-linear relationship between SBP ARV and MCI, and the inflection point of SBP ARV was 7.52. Our study found that high SBP ARV was closely associated with MCI, indicating that high SBP ARV may act as an indicator of MCI in MHD patients.
- 22 February 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-7
Open AccessCorrelation between intradialytic blood pressure variability and cognitive impairment in patients on maintenance hemodialysis
The relationship between intradialytic blood pressure variability (BPV) and mild cognitive impairment (MCI) in maintenance hemodialysis (MHD) patients is currently unclear. Our present study aimed to illustrate the correlation between intra-dialysis BPV and CI in MHD patients. Intradialytic SBP within 3 months before cognitive assessment of the patients were collected as baseline data and averaged as final data. The intradialytic SBP was converted to the following 4 candidate short-term BPV indices: standard deviation (SD), coefficient of variation (CV), average real variability (ARV), RANGE. Overall cognitive function was assessed by the Montreal Cognitive Assessment (MoCA) scale. The study finally enrolled 170 patients with 6662 dialysis records and 26,580 SBP measurements. The mean age of the patients was 57.99 years, the MCI prevalence was 78.24%. Intradialytic SBP ARV (average real variability) was notably higher in patients with MCI than in the non-MCI (NMCI) group (8.91 vs. 7.60, P = 0.042), but there was no statistical difference in the mean SBP and other BPV indices between the two groups. There was a non-linear relationship between SBP ARV and MCI, and the inflection point of SBP ARV was 7.52. Our study found that high SBP ARV was closely associated with MCI, indicating that high SBP ARV may act as an indicator of MCI in MHD patients.
- Open Access
- 11 February 2025
- Published by Probiologists Limited in Cell Signaling
- Vol. 3 (1) , 19-22
Cognitive impairment in hemodialysis needs sufficient attention
Hemodialysis is the most common form of kidney replacement worldwide. It is expected that the acceptance rate of hemodialysis will continue to increase in the coming decades.
- 11 February 2025
- Published by Probiologists Limited in Cell Signaling
- Vol. 3 (1) , 19-22
Open AccessCognitive impairment in hemodialysis needs sufficient attention
Hemodialysis is the most common form of kidney replacement worldwide. It is expected that the acceptance rate of hemodialysis will continue to increase in the coming decades.
- Open Access
- 30 May 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 460-467
Relationship between Dialysate Bicarbonate Concentration and All-Cause Mortality in Hemodialysis Patients
Introduction: The optimal dialysate bicarbonate concentration (DBIC) for hemodialysis (HD) remains controversial. Herein, we analyzed the effect of dialysate bicarbonate levels on mortality in HD patients. Methods: Patients undergoing maintenance HD were recruited from the HD unit of the Daping Hospital. Patients were categorized into quartiles according to their DBIC level (quartile 1: <31.25 mmol/L, n = 77; quartile 2: 31.25–32.31 mmol/L, n = 76; quartile 3: 32.31–33.6 mmol/L; n = 81; quartile 4: ≥33.6 mmol/L, n = 79). Demographic and clinical data were collected. Survival curves were estimated using the Kaplan-Meier method. A Cox proportional hazards regression model was used to estimate the association between DBIC and all-cause mortality. Results: We included 313 patients undergoing maintenance HD with a mean DBIC of 32.16 ± 1.59 mmol/L (range, 27.20–34.72 mmol/L). The patients in quartile 4 were more likely to have higher pre- and post-HD serum bicarbonate concentrations than those in other quartiles. The mortality rate was lowest in quartile 2 (10.53%). The survival time was significantly lower in the quartile 4 group than in the other quartiles (p = 0. 008, log-rank test). After full adjustment, the hazard ratio (per 3 mmol/L higher DBIC) for all-cause mortality was 4.29 (95% confidence interval, 2.11–8.47) in all patients, whereas no significant association was observed between DBIC and initial hospitalization. Conclusions: Our data indicate that DBIC is positively associated with all-cause mortality. A DBIC concentration of 31–32 mmol/L may benefit patient outcomes. This study provides an evidence-based medical basis for optimal dialysis prescription in the future.
- 30 May 2023
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 48 (1) , 460-467
Open AccessRelationship between Dialysate Bicarbonate Concentration and All-Cause Mortality in Hemodialysis Patients
Introduction: The optimal dialysate bicarbonate concentration (DBIC) for hemodialysis (HD) remains controversial. Herein, we analyzed the effect of dialysate bicarbonate levels on mortality in HD patients. Methods: Patients undergoing maintenance HD were recruited from the HD unit of the Daping Hospital. Patients were categorized into quartiles according to their DBIC level (quartile 1: <31.25 mmol/L, n = 77; quartile 2: 31.25–32.31 mmol/L, n = 76; quartile 3: 32.31–33.6 mmol/L; n = 81; quartile 4: ≥33.6 mmol/L, n = 79). Demographic and clinical data were collected. Survival curves were estimated using the Kaplan-Meier method. A Cox proportional hazards regression model was used to estimate the association between DBIC and all-cause mortality. Results: We included 313 patients undergoing maintenance HD with a mean DBIC of 32.16 ± 1.59 mmol/L (range, 27.20–34.72 mmol/L). The patients in quartile 4 were more likely to have higher pre- and post-HD serum bicarbonate concentrations than those in other quartiles. The mortality rate was lowest in quartile 2 (10.53%). The survival time was significantly lower in the quartile 4 group than in the other quartiles (p = 0. 008, log-rank test). After full adjustment, the hazard ratio (per 3 mmol/L higher DBIC) for all-cause mortality was 4.29 (95% confidence interval, 2.11–8.47) in all patients, whereas no significant association was observed between DBIC and initial hospitalization. Conclusions: Our data indicate that DBIC is positively associated with all-cause mortality. A DBIC concentration of 31–32 mmol/L may benefit patient outcomes. This study provides an evidence-based medical basis for optimal dialysis prescription in the future.
- 12 August 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (9) , e22472
VNN1 contributes to the acute kidney injury–chronic kidney disease transition by promoting cellular senescence via affecting RB1 expression
The mechanisms underlying acute kidney injury (AKI) and chronic kidney disease (CKD) progression include interstitial inflammation, cellular senescence, and oxidative stress (OS). Although vanin‐1 (VNN1) plays an important role in OS, its contribution to the AKI‐CKD transition remains unknown. Here, we explored the roles and mechanisms of VNN1 in the progression of the AKI‐CKD transition. We observed that VNN1 expression was upregulated after ischemia/reperfusion (I/R) injury and high VNN1 expression levels were associated with poor renal repair after I/R injury. In VNN1 knockout (KO) mice, recovery of serum creatinine and blood urea nitrogen levels after I/R injury was accelerated and renal fibrosis was inhibited after severe I/R injury. Furthermore, in VNN1 KO mice, senescence of renal tubular cells was inhibited after severe I/R injury, as assessed by P16 expression and SA‐β‐Gal assays. However, our results also revealed that VNN1 KO renal tubular cells did not resist senescence when OS was blocked. To elucidate the mechanism underlying VNN1‐mediated regulation of senescence during the AKI‐CKD transition, retinoblastoma 1 (RB1) was identified as a potential target. Our results suggest that the reduced senescence in VNN1 KO renal tubular cells was caused by suppressed RB1 expression and phosphorylation. Collectively, our results unveil a novel molecular mechanism by which VNN1 promotes AKI‐CKD transition via inducing senescence of renal tubular cells by activating RB1 expression and phosphorylation after severe renal injury. The present study proposes a new strategy for designing therapies wherein VNN1 can be targeted to obstruct the AKI‐CKD transition.
- 12 August 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (9) , e22472
VNN1 contributes to the acute kidney injury–chronic kidney disease transition by promoting cellular senescence via affecting RB1 expression
The mechanisms underlying acute kidney injury (AKI) and chronic kidney disease (CKD) progression include interstitial inflammation, cellular senescence, and oxidative stress (OS). Although vanin‐1 (VNN1) plays an important role in OS, its contribution to the AKI‐CKD transition remains unknown. Here, we explored the roles and mechanisms of VNN1 in the progression of the AKI‐CKD transition. We observed that VNN1 expression was upregulated after ischemia/reperfusion (I/R) injury and high VNN1 expression levels were associated with poor renal repair after I/R injury. In VNN1 knockout (KO) mice, recovery of serum creatinine and blood urea nitrogen levels after I/R injury was accelerated and renal fibrosis was inhibited after severe I/R injury. Furthermore, in VNN1 KO mice, senescence of renal tubular cells was inhibited after severe I/R injury, as assessed by P16 expression and SA‐β‐Gal assays. However, our results also revealed that VNN1 KO renal tubular cells did not resist senescence when OS was blocked. To elucidate the mechanism underlying VNN1‐mediated regulation of senescence during the AKI‐CKD transition, retinoblastoma 1 (RB1) was identified as a potential target. Our results suggest that the reduced senescence in VNN1 KO renal tubular cells was caused by suppressed RB1 expression and phosphorylation. Collectively, our results unveil a novel molecular mechanism by which VNN1 promotes AKI‐CKD transition via inducing senescence of renal tubular cells by activating RB1 expression and phosphorylation after severe renal injury. The present study proposes a new strategy for designing therapies wherein VNN1 can be targeted to obstruct the AKI‐CKD transition.
- Open Access
- 3 June 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (6) , 1-14
Decoy receptor 2 mediates the apoptosis-resistant phenotype of senescent renal tubular cells and accelerates renal fibrosis in diabetic nephropathy
Apoptotic resistance leads to persistent accumulation of senescent cells and sustained expression of a senescence-associated secretory phenotype, playing an essential role in the progression of tissue fibrosis. However, whether senescent renal tubular epithelial cells (RTECs) exhibit an apoptosis-resistant phenotype, and the role of this phenotype in diabetic nephropathy (DN) remain unclear. Our previous study was the first to demonstrate that decoy receptor 2 (DcR2) is associated with apoptotic resistance in senescent RTECs and renal fibrosis. In this study, we aimed to further explore the mechanism of DcR2 in apoptosis-resistant RTECs and renal fibrosis in DN. DcR2 was co-localized with fibrotic markers (α-SMA, collagen IV, fibronectin), senescent marker p16, and antiapoptotic proteins FLIP and Bcl2 but rarely co-localized with caspase 3 or TUNEL. DcR2 overexpression promoted renal fibrosis in mice with streptozotocin (STZ)-induced DN, as evidenced by augmented Masson staining and upregulated expression of fibrotic markers. DcR2 overexpression also enhanced FLIP expression while reducing the expression of pro-apoptotic proteins (caspases 8 and 3) in senescent RTECs, resulting in apoptotic resistance. In contrast, DcR2 knockdown produced the opposite effects in vitro and in vivo. Moreover, quantitative proteomics and co-immunoprecipitation experiments demonstrated that DcR2 interacted with glucose-related protein 78 kDa (GRP78), which has been shown to promote apoptotic resistance in cancer. GRP78 exhibited co-localization with senescent and antiapoptotic markers but was rarely co-expressed with caspase 3 or TUNEL. Additionally, GRP78 knockdown decreased the apoptosis resistance of HG-induced senescent RTECs with upregulated cleaved caspase 3 and increased the percentage of apoptotic RTECs. Mechanistically, DcR2 mediated apoptotic resistance in senescent RTECs by enhancing GRP78–caspase 7 interactions and promoting Akt phosphorylation. Thus, DcR2 mediated the apoptotic resistance of senescent RTECs and renal fibrosis by interacting with GRP78, indicating that targeting the DcR2–GRP78 axis represents a promising therapeutic strategy for DN.
- 3 June 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (6) , 1-14
Open AccessDecoy receptor 2 mediates the apoptosis-resistant phenotype of senescent renal tubular cells and accelerates renal fibrosis in diabetic nephropathy
Apoptotic resistance leads to persistent accumulation of senescent cells and sustained expression of a senescence-associated secretory phenotype, playing an essential role in the progression of tissue fibrosis. However, whether senescent renal tubular epithelial cells (RTECs) exhibit an apoptosis-resistant phenotype, and the role of this phenotype in diabetic nephropathy (DN) remain unclear. Our previous study was the first to demonstrate that decoy receptor 2 (DcR2) is associated with apoptotic resistance in senescent RTECs and renal fibrosis. In this study, we aimed to further explore the mechanism of DcR2 in apoptosis-resistant RTECs and renal fibrosis in DN. DcR2 was co-localized with fibrotic markers (α-SMA, collagen IV, fibronectin), senescent marker p16, and antiapoptotic proteins FLIP and Bcl2 but rarely co-localized with caspase 3 or TUNEL. DcR2 overexpression promoted renal fibrosis in mice with streptozotocin (STZ)-induced DN, as evidenced by augmented Masson staining and upregulated expression of fibrotic markers. DcR2 overexpression also enhanced FLIP expression while reducing the expression of pro-apoptotic proteins (caspases 8 and 3) in senescent RTECs, resulting in apoptotic resistance. In contrast, DcR2 knockdown produced the opposite effects in vitro and in vivo. Moreover, quantitative proteomics and co-immunoprecipitation experiments demonstrated that DcR2 interacted with glucose-related protein 78 kDa (GRP78), which has been shown to promote apoptotic resistance in cancer. GRP78 exhibited co-localization with senescent and antiapoptotic markers but was rarely co-expressed with caspase 3 or TUNEL. Additionally, GRP78 knockdown decreased the apoptosis resistance of HG-induced senescent RTECs with upregulated cleaved caspase 3 and increased the percentage of apoptotic RTECs. Mechanistically, DcR2 mediated apoptotic resistance in senescent RTECs by enhancing GRP78–caspase 7 interactions and promoting Akt phosphorylation. Thus, DcR2 mediated the apoptotic resistance of senescent RTECs and renal fibrosis by interacting with GRP78, indicating that targeting the DcR2–GRP78 axis represents a promising therapeutic strategy for DN.
- 30 March 2022
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 26 (7) , 649-658
Establishment of a novel mouse peritoneal dialysis-associated peritoneal injury model
Background Peritoneal fibrosis induced by various factors during peritoneal dialysis (PD) can eventually lead to ultrafiltration failure and termination of PD treatment. The existing animal models are caused by a single stimulus, and cannot accurately simulate complex pathogenesis of peritoneal injury and fibrosis. We aim to develop an efficient and realistic mouse model of PD-associated peritoneal injury using daily intraperitoneal injection (I.P.) of human peritonitis PD effluent. Methods Eight-week-old male C57BL/6 mice were classified into six groups: saline control; 2.5% PD fluid; 2.5% PD fluid + lipopolysaccharide (LPS); 4.25% PD fluid; 4.25% PD fluid + LPS; and peritonitis effluent. Mice received daily I.P. for 6 weeks, and were sacrificed to determine peritoneal structural and functional damage, inflammation, and fibrosis. Results Mice in the peritonitis effluent group had low mortality. The submesothelial thickness in the peritonitis effluent group was significantly greater than that in the 2.5% PD fluid group. The peritonitis effluent group had increased expression of fibrosis markers (α-SMA, Collagen I, etc.), neutrophil granulocytes (MPO), and macrophages (CD68, F4/80) in the peritoneum based on immunohistochemical staining; and significantly higher expression of inflammation markers (IL-1β, IL-6, etc.) and fibrosis markers (TGF-β1, α-SMA, etc.) based on real-time qPCR. Modified peritoneal equilibration tests (PET) demonstrated that I.P. of peritonitis effluent reduced peritoneal ultrafiltration. Conclusion Our novel animal model of PD-associated peritoneal injury faithfully simulates the clinical pathophysiological process. This animal model may be useful for study of the pathogenesis of PD-associated peritoneal injury and identification of novel treatments.
- 30 March 2022
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 26 (7) , 649-658
Establishment of a novel mouse peritoneal dialysis-associated peritoneal injury model
Background Peritoneal fibrosis induced by various factors during peritoneal dialysis (PD) can eventually lead to ultrafiltration failure and termination of PD treatment. The existing animal models are caused by a single stimulus, and cannot accurately simulate complex pathogenesis of peritoneal injury and fibrosis. We aim to develop an efficient and realistic mouse model of PD-associated peritoneal injury using daily intraperitoneal injection (I.P.) of human peritonitis PD effluent. Methods Eight-week-old male C57BL/6 mice were classified into six groups: saline control; 2.5% PD fluid; 2.5% PD fluid + lipopolysaccharide (LPS); 4.25% PD fluid; 4.25% PD fluid + LPS; and peritonitis effluent. Mice received daily I.P. for 6 weeks, and were sacrificed to determine peritoneal structural and functional damage, inflammation, and fibrosis. Results Mice in the peritonitis effluent group had low mortality. The submesothelial thickness in the peritonitis effluent group was significantly greater than that in the 2.5% PD fluid group. The peritonitis effluent group had increased expression of fibrosis markers (α-SMA, Collagen I, etc.), neutrophil granulocytes (MPO), and macrophages (CD68, F4/80) in the peritoneum based on immunohistochemical staining; and significantly higher expression of inflammation markers (IL-1β, IL-6, etc.) and fibrosis markers (TGF-β1, α-SMA, etc.) based on real-time qPCR. Modified peritoneal equilibration tests (PET) demonstrated that I.P. of peritonitis effluent reduced peritoneal ultrafiltration. Conclusion Our novel animal model of PD-associated peritoneal injury faithfully simulates the clinical pathophysiological process. This animal model may be useful for study of the pathogenesis of PD-associated peritoneal injury and identification of novel treatments.